Philippe Vago

Clermont Université

Papers

1

Total Citations

16

H-Index

1

About

Philippe Vago is a hematologist-oncologist whose research focuses on the molecular mechanisms of myeloproliferative neoplasms (MPNs) and chronic myeloid leukemia (CML), particularly the interplay between BCR-ABL and JAK2 mutations. His most-cited work, a 2009 study, revealed a critical clinical insight: patients with Philadelphia-positive CML achieving molecular remission on imatinib can develop a thrombocytosis driven by an underlying JAK2V617F mutation, highlighting the coexistence of distinct MPN clones. This finding has shaped diagnostic approaches for treatment-emergent thrombocytosis, emphasizing the need for vigilant molecular monitoring. With over 16 citations, this paper underscores his contribution to understanding clonal heterogeneity in MPNs. Vago’s broader work integrates molecular pathology with clinical management, advancing personalized therapies for hematologic malignancies. His research has been instrumental in refining risk stratification and therapeutic strategies, bridging basic science and bedside practice. For students and researchers, Vago’s studies exemplify how unexpected clinical observations can unravel complex disease biology, offering a model for translational investigation in hematology.

Research Focus

Key Achievements

1
H-Index
1
Papers
16
Total Citations
16
Avg Citations/Paper
🏆 Most Cited Paper
A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2V617F myeloproliferative neoplasm
16 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Clermont Université

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago